Market Size, Demand & Growth

The global oxygen therapy equipment market was worth roughly $3.41 billion in 2025 and is forecast to climb toward $4.95 billion by 2034, a compound annual growth rate of about 4.3% (Fortune Business Insights, 2025). That is a steady, defensible market rather than a hype curve, which is exactly what lenders underwriting a respiratory durable medical equipment (DME) supplier want to see.

The detail that matters for your plan is where the demand sits. Homecare settings already account for 55.8% of the market, and the home channel is the fastest-growing slice at roughly 8.0% a year (market.us, 2025). An ageing population, rising COPD and pulmonary fibrosis prevalence, and the post-pandemic normalisation of home oxygen therapy (HOT) all push patients out of the hospital and into the living room. A new supplier does not compete with hospital procurement; it competes for the prescriptions that flow to the home.

Within the category, the oxygen concentrator sub-market is the engine. It is projected to reach $1.71 billion by 2030 at a 6.1% CAGR (MarketsandMarkets, 2025), with portable units the standout segment as patients refuse to be tethered to the house. Your business plan should pick a lane inside this: stationary long-term oxygen therapy, ambulatory and travel portable oxygen concentrators (POCs), or a mixed fleet that captures both the reimbursed rental and the cash-pay traveller.

The supply side is consolidated around a handful of device makers, which is useful context for the vendor section of your plan. Most fleets are built from Inogen, CAIRE (part of Chart Industries, including the AirSep and SeQual lines), Philips Respironics, ResMed, Invacare, Drive DeVilbiss, O2 Concepts, and Precision Medical. Naming a primary and a backup vendor, and explaining the warranty and service terms behind them, signals to a lender that you have thought past the brochure.

Demand for home oxygen is unusually predictable because it tracks chronic disease rather than discretionary spending. COPD alone affects an enormous and growing patient base, and pulmonary fibrosis, severe asthma, heart failure, and post-COVID respiratory damage all feed long-term oxygen therapy prescriptions. That durability is a double-edged sword for your plan: it makes revenue forecastable, but it also means the market is mature and the incumbents are entrenched. A new supplier wins on responsiveness, delivery density, and referral relationships, not on being first to a brand-new category. Say that plainly in the market section and a lender will trust the rest of your numbers more.

Where new entrants actually win

The referral pathway is the real market. Oxygen patients almost never shop for a supplier; a pulmonologist, hospital discharge planner, or sleep clinic routes them to whoever is contracted, fast, and reliable. Your plan's market section should therefore map the prescribers in your catchment, not just the patients. A local hospital discharging COPD patients on home oxygen each week is worth more than any advertising budget, and a supplier that can promise same-day setup and a four-hour emergency response becomes the default choice. Geographic density compounds this: a tight delivery radius means lower fuel and labour cost per patient, which is why most successful single-site operators win one metro before expanding rather than spreading thin.

SBA & Lender Funding for a Respiratory DME

Oxygen equipment is a rental-and-service business, so it is capital-hungry before it is cash-positive. You buy concentrators, cylinders, and a delivery vehicle up front, then wait through Medicare enrolment and payer credentialing before the first reimbursement clears. That working-capital gap is the single biggest reason oxygen startups stall, and it is exactly what an SBA-backed loan is designed to bridge.

How DME founders typically fund the launch

• SBA 7(a) loan, the workhorse for DME, lending up to $5M over terms as long as 10 years for equipment and working capital. Lenders expect a 5-year projection that models the 36-month rental cap, not flat per-patient revenue.
• SBA 504 / equipment financing, when the bulk of the raise is the concentrator and cylinder fleet, asset-backed financing can sit alongside a smaller working-capital line.
• Equipment leasing lines, manufacturers and third-party lessors will finance the rental fleet so cash is preserved for accreditation, the surety bond, and payroll.
• Founder equity, most banks want to see 10-20% owner injection; respiratory therapists turned operators often contribute relationships and clinical credibility in place of a larger cheque.

Whichever route you take, the document doing the heavy lifting is the financial model. A respiratory DME plan that survives underwriting shows the bond, accreditation, and credentialing timeline as a cash drain in months 1-6, then ramps reimbursed rentals as patients are added. Our $300/£250 and $1,000/£800 packages build that model in Excel with the income statement, cash flow, and break-even already wired together. If you are weighing related models, our durable medical equipment business plan template and medical equipment rental business plan template cover adjacent funding structures.

What lenders stress-test in a DME plan

Banks underwriting an oxygen supplier focus on three numbers. First, days-to-cash: how long from launch until your first reimbursement clears, given the bond, accreditation, and credentialing runway. Second, collections risk: Medicare and Medicaid pay slowly and audit aggressively, so a plan that shows clean documentation processes and a denial-management workflow reads as lower risk. Third, the new-patient engine: because the rental cap retires patients off revenue, the lender wants evidence that referrals are contracted or relationship-backed, not assumed. A plan that addresses all three before the lender raises them is far more likely to clear committee. This is also where founder credibility carries real weight; a Registered Respiratory Therapist with existing pulmonologist relationships de-risks the referral engine in a way no spreadsheet can.

Why the model is harder than it looks

Oxygen forecasting trips up first-time founders because revenue and cost move on different clocks. A new patient costs you a delivery, a setup visit, and a machine off the shelf on day one, but pays back over months of rental. Capped patients keep costing you service while paying nothing. Layer in slow payer remittance and the cash-flow curve dips well below the revenue curve in the first year. A credible model separates accrual revenue from collected cash and shows the working-capital trough explicitly, so the funding ask matches the deepest point of the curve rather than the average.

Startup Capital & Cost Stack

A single-site home oxygen supplier in the US typically needs $50,000 to $150,000 to reach its first clean claim, and a UK respiratory equipment business roughly £35,000 to £110,000. The numbers are driven less by the equipment itself and more by the cost of becoming billable: the surety bond, accreditation, licensing, and the months of payroll you carry before reimbursement arrives.

Where the money goes

• DMEPOS surety bond: $50,000 bond required per NPI; you pay only the annual premium of roughly $275-$2,500 depending on credit (Surety1, 2026)
• CMS-approved accreditation (single site): $2,500-$5,000 to ACHC, BOC, CHAP, or The Joint Commission
• State DME / oxygen licence: $300-$2,000 (e.g. Florida around $304.50 plus a $400 inspection fee)
• Rental fleet (concentrators, cylinders, conserving devices): $25,000-$70,000 to seed the first wave of patients
• Billing & patient-management software: $3,000-$12,000 setup (Brightree, NikoHealth and similar)
• Delivery vehicle, liability & professional insurance: $8,000-$20,000
• Working capital (3-6 months payroll + overhead): the buffer that carries you through credentialing

The UK cost base looks different because the route to revenue is different. There is no $50,000 bond and no Medicare enrolment; instead, home oxygen flows through NHS regional contracts, so a UK plan spends its capital on MHRA device registration, an ISO 13485 quality system, fleet, and the bid resources needed to compete for regional tenders. We cover that contrast in the compliance section below.

Fixed versus variable: read the cost stack correctly

Not all of these costs behave the same way, and your plan should split them. The surety bond, accreditation, software setup, and licensing are largely fixed: you pay them once to open the door, regardless of patient count. The fleet, consumables, delivery labour, and fuel are variable and scale with patients. That split matters because it sets your break-even. A supplier with a heavy fixed base needs more patients to cover overhead, but every patient beyond break-even drops a high margin to the bottom line. Showing the fixed and variable split, and the patient count where they cross, is the difference between a forecast that looks plausible and one a lender can actually test.

One more line item founders forget: the cost of denials and rework. A meaningful share of early DME claims bounce on documentation, the certificate of medical necessity, the qualifying blood-gas or oximetry test, or the prescription detail. Each denial is unpaid labour and delayed cash. Budget for a billing specialist or an outsourced revenue-cycle partner from day one rather than treating clean claims as a given; it is cheaper than the cash-flow hole that sloppy documentation creates.

Equipment & Fleet Checklist

The fleet is the balance sheet. Underbuy and you turn away referrals; overbuy and you sink cash into idle machines before patients are credentialed. Use this checklist to size the opening fleet and to name vendors in the operations section of your plan.

• Stationary oxygen concentrators (5L): $600-$1,200 each as rental stock; the core of long-term oxygen therapy billing (HCPCS E1390)
• Portable oxygen concentrators (POCs): $1,500-$3,200 each retail; CAIRE units alone span roughly $1,500-$3,200, with cash-pay travel rentals often $2,000-$4,000
• Compressed gas cylinders & ambulatory tanks: cylinders, regulators, and conserving devices for patients who need portability beyond a POC
• Liquid oxygen (LOX) systems: optional, higher-flow patients; heavier logistics and refill infrastructure
• CPAP / BiPAP & respiratory accessories: a natural cross-sell that lifts per-patient lifetime value beyond the oxygen rental cap
• Pulse oximeters, cannulas, tubing, humidifiers: consumables bundled into the oxygen allowance under Medicare, so budget them as cost, not revenue
• Delivery, set-up and service kit: vehicle, backup equipment, and the same-day / emergency response capability patients and clinicians expect

Name your primary manufacturer and a backup. A plan that says "concentrators from Inogen and CAIRE, with Philips Respironics as a secondary line, all under manufacturer warranty and a documented preventive-maintenance schedule" reads very differently from one that just lists "oxygen machines." That specificity is what separates a fundable respiratory DME plan from a generic medical-supply template.

Sizing the opening fleet is a judgement call worth showing your work on. Order too few units and you turn away the referrals that are hardest to win back; order too many and idle machines depreciate on the shelf while your bond and accreditation cash is already spent. A practical rule for a single-site launch is to seed enough stationary concentrators to cover your first 60-90 days of projected new patients, with a 15-20% buffer for service swaps and backup units, then reorder against actual intake. Pair that with a maintenance log and a preventive-service interval per manufacturer specification, because accreditation surveyors will ask to see it and payers can claw back payment if equipment is not serviced to standard. Treat the fleet as a managed asset with a lifecycle, not a one-time purchase, and both your operations plan and your depreciation schedule become easy to defend.

Reimbursement & Unit Economics

Home oxygen is not a product sale; under Medicare and most US insurers it is a capped rental. A stationary concentrator (HCPCS E1390) reimburses at roughly $70 to $140 per month depending on the region, with payment increased above 4 litres per minute and reduced below 1 litre per minute (CMS Policy Article A52514). The accessories, cannulas, tubing, delivery, backup equipment, and routine service are all folded into that monthly allowance, so the headline rate is the whole rate.

The number that defines the entire model is the 36-month rental cap. Medicare pays no more than 36 continuous monthly rental payments for oxygen equipment. After that, the supplier keeps the same machine in the patient's home for a further 24 months and is paid only for maintenance and servicing, no more often than every six months. In other words, a patient who has been on service for three years stops generating rental revenue while still consuming delivery and support. A plan that models flat per-patient income forever is simply wrong, and a sharp lender will catch it.

A worked example

Suppose your steady-state book holds 250 stationary concentrators inside their first 36 months at a blended $115/month. That is roughly $345,000 a year in stationary rental revenue. Because the cap retires older patients off the rental clock, holding that figure requires a steady stream of new prescriptions each month. The operators who build durable margin layer additional revenue on top: ambulatory portable rentals, CPAP and BiPAP, and cash-pay travel POCs sold or rented outside the reimbursement cap at $2,000-$4,000 retail. Stack those streams and net margins land in the 10-25% range once payer contracts mature and delivery routes are dense enough to be efficient.

The strategic takeaway for your plan: model new-patient intake explicitly, treat the cap as a feature of the cash-flow forecast rather than a footnote, and show how cross-sell offsets the rental cliff. That single piece of realism is what most oxygen business plans miss.

The three revenue streams to model separately

A strong oxygen plan does not forecast one blended revenue line; it models three streams with different economics. Reimbursed rental is the foundation: stationary and portable concentrators paid by Medicare, Medicaid, and commercial insurers under the 36-month cap, predictable but rate-controlled and slow to collect. Cash-pay sales and rentals are the margin booster: travel POCs for patients who fly, backup units, and accessories sold outright at $2,000-$4,000 with no cap and immediate payment. Service and maintenance is the long tail: the capped maintenance payments after month 36, plus repair and replacement work that keeps a relationship alive even when rental income has stopped. Showing each stream's volume, rate, and collection timing turns a vague "we sell oxygen" pitch into a model a lender can underwrite.

Density is the quiet lever behind all of it. Two suppliers can bill the same per-patient rate and earn wildly different margins depending on how tightly their patients cluster. Twenty patients spread across a county burn a technician's whole day in driving; twenty patients in three adjacent suburbs are a two-hour route. When you project margin, tie it to route density and patients-per-technician, not just headline reimbursement. That is the operational insight most business plans on this topic skip entirely, and it is exactly where a focused single-site operator beats a sprawling national competitor.

Accreditation, Licensing & Compliance

Oxygen is regulated as both a medical device and, in many places, a drug. You cannot bill until you have cleared accreditation and enrolment, and the timeline for that is the real launch schedule. Build it into the plan as a gate, not an afterthought.

United States

• Enrol as a DMEPOS supplier via CMS form 855S through the National Provider Enrollment DMEPOS East/West contractor; PECOS processing runs roughly 45-60 days and revalidation is every three years
• Post a $50,000 surety bond for each NPI you maintain
• Hold accreditation from a CMS-approved body (ACHC, BOC, CHAP, The Joint Commission) against the DMEPOS Quality Standards, including an unannounced site visit, typically 3-9 months
• Obtain a state DME or oxygen licence; several states require an affiliated licensed pharmacist or respiratory therapist specifically because you are dispensing oxygen
• Add Medicaid and commercial credentialing, which can extend the runway by a further 2-4 months

United Kingdom

• Home oxygen is commissioned through NHS regional contracts; clinicians submit a Home Oxygen Order Form (HOOF) to the contracted supplier rather than billing you directly
• Incumbents such as Baywater Healthcare (serving 40,000+ patients) and Air Liquide Healthcare hold these regional contracts, with emergency-delivery service levels as tight as four hours
• Register medical devices with the MHRA and meet UKCA/CE conformity under an ISO 13485 quality system
• Where you provide clinical assessment or oxygen titration, register with the Care Quality Commission (CQC)

Canada (Ontario)

• The Assistive Devices Program (ADP) funds 75% of basic home-oxygen rental, with the patient paying 25%, and 100% covered when professional services run through Ontario Health atHome (Government of Ontario)
• Suppliers must be ADP-registered, and a Registered Respiratory Therapist typically completes the funding application
• Federal medical device licensing is handled through Health Canada (Medical Device Establishment Licence)

The practical lesson across all three markets: the same patient, the same machine, three completely different money flows. A credible plan states which jurisdiction it is built for and models the funding mechanism that actually applies, rather than assuming a single global system.

Compliance is not a one-off hurdle either; it is an operating cost that recurs. US suppliers revalidate their DMEPOS enrolment every three years and maintain accreditation through periodic unannounced surveys, so the plan should carry the ongoing audit, documentation, and quality-management burden as a line in years two through five, not just at launch. The same discipline that gets you accredited, clean prescriptions, qualifying test results, certificates of medical necessity, and a documented service history, is what protects you from recoupment later. Investors and lenders who have seen DME businesses unravel under audit will look specifically for this, so a plan that treats compliance as a living system rather than a checkbox stands out.

Mistakes That Sink Oxygen Startups

Across respiratory DME plans we review, the same five errors recur. Each is easy to fix on paper and expensive to discover after launch.

• Ignoring the 36-month cap. A model that assumes a patient pays rental forever overstates steady-state cash flow by a wide margin. Build the cap into the forecast and show new-patient intake replacing capped patients.
• Underbudgeting the cost of becoming billable. Founders fund the vans and machines, then run out of cash before the surety bond, accreditation, and credentialing clear. Carry 3-6 months of working capital.
• Treating oxygen like generic retail. Several states require a pharmacist or respiratory-therapist affiliation for oxygen. Missing that turns a "we'll register later" line into a launch-blocking surprise.
• No delivery and service logistics. Same-day and emergency delivery are the product, not a perk. A plan with no route density, backup equipment, or response-time commitment will not win referrals.
• Assuming the UK works like the US. Home oxygen in Britain runs through NHS regional contracts and the HOOF, so a direct-billing model copied from a US plan simply does not apply.

A sixth, subtler error is competing on price. Oxygen reimbursement rates are largely fixed by the payer, so there is little room to "win on cost" against a national supplier with stronger procurement buying power. The durable advantage is service: faster setup, tighter delivery windows, real emergency response, and a referral relationship the prescriber trusts. Build the plan around that, and the competitive section writes itself around proof points rather than a price war you cannot win. The same logic applies when you eventually expand: a second site only makes sense once the first has dense routes and reliable referral volume, because spreading a thin patient base across two delivery operations doubles fixed cost without doubling revenue. Sequence growth deliberately in the plan, and the expansion story reads as disciplined rather than speculative.

Sample Business Plan Preview

Here's an extract from an oxygen therapy equipment business plan written by our team, so you can see the level of specificity you'll get:

What's in the Template

Every Avvale business plan template is pre-structured for your industry. For an oxygen therapy equipment supplier, the sections are tuned to what payers and lenders actually scrutinise:

• Executive Summary, Your supplier concept, target jurisdiction, and funding ask in 60 seconds
• Company Overview, Legal structure, NPI plan, ownership, and the founder's clinical or operational credibility
• Market Analysis, Home oxygen demand, COPD prevalence, and the concentrator vs cylinder vs POC mix
• Customer & Referral Analysis, Pulmonologists, hospital discharge planners, and the prescription pathway
• Competitor Analysis, Local DME suppliers plus the national manufacturers behind every fleet
• Operations & Logistics Plan, Delivery routing, set-up, service intervals, and emergency response
• Compliance & Accreditation Plan, DMEPOS, surety bond, state licensing, and the credentialing timeline
• Management Team, Founder bio, respiratory-therapist affiliations, and key hires

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and a reimbursement schedule that respects the 36-month oxygen rental cap. Browse the full set of free business plan templates if you operate more than one line.

What makes the oxygen version of each section different from a generic medical-supply plan is the regulatory and reimbursement detail baked in. The operations plan accounts for delivery routing and emergency response; the financial model treats rental as capped rather than perpetual; the compliance section sequences the bond, accreditation, and credentialing in the order they actually happen; and the management section foregrounds the clinical credibility, often a respiratory therapist, that de-risks the referral engine. Those are not cosmetic tweaks. They are the specific things a DME lender, a payer credentialing committee, or an accreditation surveyor looks for, and they are why a tuned template clears review faster than a blank document or a one-size-fits-all download.

Frequently Asked Questions